Cargando…

Transient appearance of circulating tumor DNA associated with de novo treatment

The limitation of circulating tumor DNA (ctDNA) is its inability to detect cancer cell subpopulations with few or no dying cells. Lung cancer patients subjected to the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment were prospectively collected, and ctDNA levels represented by the activating and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Kikuya, Uchida, Junji, Kukita, Yoji, Kumagai, Toru, Nishino, Kazumi, Inoue, Takako, Kimura, Madoka, Imamura, Fumio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146655/ https://www.ncbi.nlm.nih.gov/pubmed/27934896 http://dx.doi.org/10.1038/srep38639

Ejemplares similares

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
por: Imamura, Fumio, et al.
Publicado: (2016)

Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients
por: Kato, Kikuya, et al.
Publicado: (2016)

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment
por: Uchida, Junji, et al.
Publicado: (2016)

Quantitative Identification of Mutant Alleles Derived from Lung Cancer in Plasma Cell-Free DNA via Anomaly Detection Using Deep Sequencing Data
por: Kukita, Yoji, et al.
Publicado: (2013)

A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation
por: Imamura, Fumio, et al.
Publicado: (2016)

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots
por: Imamura, Fumio, et al.
Publicado: (2015)

High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients
por: Kukita, Yoji, et al.
Publicado: (2015)

Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer
por: Kimura, Madoka, et al.
Publicado: (2017)

Afatinib-induced severe esophagitis in a lung cancer patient with an activated epidermal growth factor receptor mutation: A case report
por: Inoue, Takako, et al.
Publicado: (2017)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

Pleural sarcoidosis diagnosed on the basis of an increased CD4/CD8 lymphocyte ratio in pleural effusion fluid: a case report
por: Kumagai, Toru, et al.
Publicado: (2015)

Pembrolizumab-induced acute thrombosis: A case report
por: Kunimasa, Kei, et al.
Publicado: (2018)

Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment
por: Kunimasa, Kei, et al.
Publicado: (2019)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report
por: Nishino, Kazumi, et al.
Publicado: (2020)

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
por: Kunimasa, Kei, et al.
Publicado: (2020)

HLA genotyping by next-generation sequencing of complementary DNA
por: Segawa, Hidenobu, et al.
Publicado: (2017)

HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1
por: Kumagai, Toru, et al.
Publicado: (2018)

Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection
por: Akazawa, Yuki, et al.
Publicado: (2017)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

Infectious pericarditis caused by Gemella sanguinis induced by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A case report
por: Inoue, Takako, et al.
Publicado: (2020)

Manual route modification using an oblique method following automatic virtual bronchoscopic navigation
por: Inoue, Takako, et al.
Publicado: (2022)

Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
por: Kanazu, Masaki, et al.
Publicado: (2020)

Characterization of the T‐cell receptor beta chain repertoire in tumor‐infiltrating lymphocytes
por: Nakanishi, Katsumi, et al.
Publicado: (2016)

Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter
por: Kukita, Yoji, et al.
Publicado: (2018)

Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single‐center retrospective study
por: Kunimasa, Kei, et al.
Publicado: (2022)

Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
por: Kunimasa, Kei, et al.
Publicado: (2021)

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
por: Hattori, Yoshihiro, et al.
Publicado: (2020)

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
por: Kunimasa, Kei, et al.
Publicado: (2022)

High‐throughput screening in colorectal cancer tissue‐originated spheroids
por: Kondo, Jumpei, et al.
Publicado: (2018)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs
por: Kukita, Yoji, et al.
Publicado: (2016)

Comparison of sampling methods for next generation sequencing for patients with lung cancer
por: Kunimasa, Kei, et al.
Publicado: (2022)

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region
por: Kanemoto, Manabu, et al.
Publicado: (2014)

Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics
por: Kato, Kikuya, et al.
Publicado: (2023)

Conversion of a molecular classifier obtained by gene expression profiling into a classifier based on real-time PCR: a prognosis predictor for gliomas
por: Kawarazaki, Satoru, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_kicnu2j8u6uj8flemon32s3lba